Acute respiratory infections are frequently brought on by RSV (Respiratory syncytial virus). RSV has the ability to take advantage of host immunity and trigger a significant inflammatory response that damages the lungs and spreads the virus. A and B are the two main antigenic subgroups of the one RSV serotype.
RSV is a non-segmented, negative-sense, single-stranded enveloped RNA virus that is a member of the Pneumovirinae subfamily of the Paramyxoviridae family and the Pneumovirus genus. Since two overlapping open reading frames in the M2 mRNA result in two different matrix proteins, M2-1 and M2-2, its 10 genes encode 11 proteins. The G glycoprotein, the F glycoprotein, and the SH protein are the three proteins that make up the viral envelope. The RSV virus has two non-structural proteins (NS1 and NS2) in addition to the large (L) protein, nucleocapsid (N), phosphoprotein (P), matrix (M), and M2-1.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V54313 | RSV L-protein-IN-4 | 851657-60-8 | RSV L-Protein-IN-4 (Compound C) is a noncompetitive RSV polymerase inhibitor (IC50= 0.88 μM). |
|
V54314 | RSV L-protein-IN-5 | 851658-28-1 | RSV L-protein-IN-5 (compound E) is a potent inhibitor of respiratory syncytial virus (RSV) (EC50=0.1 μM). |
|
V35012 | RSV-IN-1 | 861139-16-4 | RSV-IN-1 is an inhibitor (blocker/antagonist) of human respiratory syncytial virus (hRSV) with IC50 of 0.11 μM. |
|
V54315 | RSV-IN-2 | 2448519-26-2 | RSV-IN-2 is a potent dual (bifunctional) inhibitor of wild-type and mutant respiratory syncytial virus fusion proteins (wild-type, EC50 = 0.27 nM; D486N mutant, EC50 = 0.70 nM). |
|
V35245 | Suptavumab (REGN2222) | 1629615-23-1 | Suptavumab (REGN2222) is a human monoclonal antibody (mAb). |
|
V54359 | Zelicapavir (RSV-IN-7) | 2070852-76-3 | Zelicapavir (RSV-IN-7) is an RSV inhibitor (EC50= < 0.4 μM). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
